Assignee
MEI PHARMA INC
US·28 granted patents·20 pending applications·147 citations·filing 2012–2023
Top patents by PatentIndex Score
48 records- 0198US9138478B2Substituted chroman derivatives, medicaments and use in therapyMEI PHARMA INC·Filed 2014·Granted Sep 22, 2015·13 cites·9 claims
- 0297US11723893B2Isoflavonoid compositions and methods for the treatment of cancerMEI PHARMA INC·Filed 2021·Granted Aug 15, 2023·5 cites·12 claims
- 0397US9381186B2Substituted chroman derivatives, medicaments and use in therapyMEI PHARMA INC·Filed 2015·Granted Jul 5, 2016·13 cites·6 claims
- 0497US9198895B2Chroman derivatives, medicaments and use in therapyMEI PHARMA INC·Filed 2015·Granted Dec 1, 2015·16 cites·10 claims
- 0597US8957109B2Chroman derivatives, medicaments and use in therapyMEI PHARMA INC·Filed 2013·Granted Feb 17, 2015·19 cites·19 claims
- 0696US10973799B2Isoflavonoid compositions and methods for the treatment of cancerMEI PHARMA INC·Filed 2019·Granted Apr 13, 2021·6 cites·9 claims
- 0795US9981936B2Isoflavonoid compositions and methods for the treatment of cancerMEI PHARMA INC·Filed 2017·Granted May 29, 2018·10 cites·14 claims
- 0894US11583514B2Isoflavonoid compounds and methods for the treatment of cancerMEI PHARMA INC·Filed 2020·Granted Feb 21, 2023·4 cites·8 claims
- 0994US10369132B2Isoflavonoid compositions and methods for the treatment of cancerMEI PHARMA INC·Filed 2018·Granted Aug 6, 2019·9 cites·15 claims
- 1092US10105346B2Isoflavonoid compounds and methods for the treatment of cancerMEI PHARMA INC·Filed 2017·Granted Oct 23, 2018·9 cites·8 claims
- 1191US11400097B2(Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseasesMEI PHARMA INC·Filed 2020·Granted Aug 2, 2022·2 cites·7 claims
- 1290US10335415B2(Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseasesMEI PHARMA INC·Filed 2018·Granted Jul 2, 2019·6 cites·21 claims
- 1390US10064868B2(Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseasesMEI PHARMA INC·Filed 2015·Granted Sep 4, 2018·7 cites·15 claims
- 1489US10603324B2(Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseasesMEI PHARMA INC·Filed 2019·Granted Mar 31, 2020·5 cites·19 claims
- 1588US11351176B2Combination therapyMEI PHARMA INC·Filed 2018·Granted Jun 7, 2022·4 cites·19 claims
- 1688US11304953B2Combination therapyMEI PHARMA INC·Filed 2018·Granted Apr 19, 2022·4 cites·19 claims
- 1784US9402829B2Benzimidazole derivatives: preparation and pharmaceutical applicationsMEI PHARMA INC·Filed 2015·Granted Aug 2, 2016·4 cites·8 claims
- 1883US12059422B2(Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseasesMEI PHARMA INC·Filed 2022·Granted Aug 13, 2024·0 cites·9 claims
- 1983US9717713B2Benzimidazole derivatives: preparation and pharmaceutical applicationsMEI PHARMA INC·Filed 2016·Granted Aug 1, 2017·3 cites·4 claims
- 2083US2023145478A1Isoflavonoid compounds and methods for the treatment of cancerMEI PHARMA INC·Filed 2023·Application pending·0 cites
- 2182US9024029B2Benzimidazole derivatives: preparation and pharmaceutical applicationsMEI PHARMA INC·Filed 2013·Granted May 5, 2015·4 cites·8 claims
- 2279US10980774B2Combination therapiesMEI PHARMA INC·Filed 2016·Granted Apr 20, 2021·2 cites·6 claims
- 2376US10201527B2Benzimidazole derivatives: preparation and pharmaceutical applicationsMEI PHARMA INC·Filed 2017·Granted Feb 12, 2019·1 cites·9 claims
- 2473US2016287555A1Substituted chroman derivatives, medicaments and use in therapyMEI PHARMA INC·Filed 2016·Application pending·0 cites
- 2572US12161644B2Combination therapyMEI PHARMA INC·Filed 2022·Granted Dec 10, 2024·0 cites·15 claims
- 2671US8901149B2Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applicationsMEI PHARMA INC·Filed 2014·Granted Dec 2, 2014·1 cites·10 claims
- 2770US10736881B2Benzimidazole derivatives: preparation and pharmaceutical applicationsMEI PHARMA INC·Filed 2018·Granted Aug 11, 2020·0 cites·16 claims
- 2869US2019142790A1Isoflavonoid compounds and methods for the treatment of cancerMEI PHARMA INC·Filed 2018·Application pending·0 cites
- 2967US2022265673A1Combination therapyMEI PHARMA INC·Filed 2022·Application pending·0 cites
- 3065US2016136129A1Chroman derivatives, medicaments and use in therapyMEI PHARMA INC·Filed 2015·Application pending·0 cites
- 3162US2025177409A1Combination therapy of pi3k inhibitor and pd-1 inhibitorMEI PHARMA INC·Filed 2023·Application pending·0 cites
- 3261US10626092B2Polymorphic forms of 3-[(2-butyl-1-(2-diethylamino-ethyl)-1H-benzoimidazol-5-yl]-N-hydroxy-acrylamide and uses thereofMEI PHARMA INC·Filed 2017·Granted Apr 21, 2020·0 cites·13 claims
- 3361US9266882B2Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applicationsMEI PHARMA INC·Filed 2014·Granted Feb 23, 2016·0 cites·11 claims
- 3460US2021100775A1Combination therapiesMEI PHARMA INC·Filed 2020·Application pending·0 cites
- 3557US2024197680A1Voruciclib dosing regimens and methods of treatment including the sameMEI PHARMA INC·Filed 2022·Application pending·0 cites
- 3655US2023233519A1Combination therapiesMEI PHARMA INC·Filed 2021·Application pending·0 cites
- 3755US2024016781A1Treatment of kras mutant cancersMEI PHARMA INC·Filed 2021·Application pending·0 cites
- 3855US2023129089A1Preparation of a 1,3,5-triazinyl benzimidazoleMEI PHARMA INC·Filed 2021·Application pending·0 cites
- 3952US2021196725A1Treatment of relapsed follicular lymphomaMEI PHARMA INC·Filed 2019·Application pending·0 cites
- 4052US2020317621A1Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ethyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide and uses thereofMEI PHARMA INC·Filed 2020·Application pending·0 cites
- 4152US2021161909A1Combination therapyMEI PHARMA INC·Filed 2019·Application pending·0 cites
- 4251US12421216B2Voruciclib polymorphs and methods of making and using thereofMEI PHARMA INC·Filed 2020·Granted Sep 23, 2025·0 cites·17 claims
- 4350US2021000838A1Combination therapyMEI PHARMA INC·Filed 2019·Application pending·0 cites
- 4449US2015258068A1Combination therapiesMEI PHARMA INC·Filed 2013·Application pending·0 cites
- 4548US2022016082A1Combination therapies for high and very high risk mdsMEI PHARMA INC·Filed 2019·Application pending·0 cites
- 4645US2021299134A1Treatment of b cell malignanciesMEI PHARMA INC·Filed 2019·Application pending·0 cites
- 4745US2019201409A1Combination therapyMEI PHARMA INC·Filed 2017·Application pending·0 cites
- 4841US2014088102A1(alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseasesMEI PHARMA INC·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when MEI PHARMA INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →